NEPHROS NEPH 深 沪
等待开盘 11-03 09:30:00 美东时间
5.70
+0.090
+1.60%
华盛通- 最 高5.90
- 今 开5.63
- 成交量 8.97万股
- 最 低 5.31
- 昨 收 5.61
- 总市值 6042.34万
- 52周最高 5.98
- 市盈率 静 814.29
- 换手率 0.85%
- 52周最低 1.39
- 委 比 -80.61%
- 总股本 1060.06万
- 历史最高 11.666
- 量 比 1.35
- 振 幅 10.52%
- 历史最低 0.905
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call
*Nephros, Inc. announces it will release third-quarter financial results on November 6, 2025, after market close and host a conference call at 4:30pm ET. Participants can join via domestic access: 1 (844) 808-7106 or international access: 1 (412) 317-5285, and ask to be connected to the Nephros conference. An audio archive will be available on the Nephros Investor Relations page shortly after the call and replay available until November 13, 2025,...
10-30 20:00
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics announced its Board has adopted a limited-duration stockholder rights plan to safeguard against rapid accumulation of its shares by investors. The plan aims to protect shareholder interests, ensure fair participation in strategic reviews, and prevent control without a premium. It does not hinder the Board from exploring strategic alternatives. The rights will trigger if any entity gains 15% ownership without Board approval,...
10-27 20:29
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics Inc. announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder (SAD) did not meet its primary or secondary endpoints. The company plans to discontinue further development of the SAD program and evaluate next steps for BNC210 in post-traumatic stress disorder (PTSD). Neuphoria will conduct a strategic review of its operations and portfolio. The company has $14.2 million in cash and expects to f...
10-20 20:15
Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
Nephros, Inc. has launched its new 19-Series PFAS Filter, designed to reduce Total PFAS in drinking water. Unlike most filters that target only PFOA and PFOS, this product addresses a broader range of PFAS contaminants, which are persistent and harmful to human health. The filter also removes other hazardous substances such as lead and asbestos, offering comprehensive protection. Key features include NSF certification, high capacity, and suitabil...
10-08 13:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Maxim Group Maintains Buy on Nephros, Raises Price Target to $6
Maxim Group analyst Anthony Vendetti maintains Nephros (NASDAQ:NEPH) with a Buy and raises the price target from $4.5 to $6.
08-09 06:58
Nephros shares are trading higher after the company reported better-than-expected Q2 financial results.
Nephros shares are trading higher after the company reported better-than-expect...
08-08 20:58
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Nephros Schedules Second Quarter 2025 Financial Results Conference Call
Nephros Inc. (NEPH), a leading water technology company, has announced it will release its second-quarter financial results on August 7, 2025, and host a conference call at 4:30pm ET the same day. Participants can join via the provided domestic or international dial-in numbers. An audio archive and replay options will be available post-call. Nephros specializes in water filtration solutions for medical and commercial markets. Investor contacts ar...
07-31 20:00
12 Industrials Stocks Moving In Thursday's After-Market Session
Gainers Babcock & Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NY...
05-09 05:05
